Icaritin Ph I Result Presents at 2014 CSCO
Sep. 18th, 2014, Xiamen, China
The 17th CSCO (Chinese Society of Clinical Oncology) annual meeting will be held in September 17th-21th, 2014, in Xiamen, China. CSCO annual meeting represents the highest level and most latest clinical oncology research of China, providing great opportunities for worldwide communication and cooperation on clinical oncology. The theme of this year is “Improve Standardized Treatment Level, Broaden International Perspective”. On the HCC symposium, Dr. Ying Fan, associate chief physician from Hospital of Chinese Academy of Medical Sciences, Sub-I of Icaritin clinical trial, will give an oral presentation named “Oral dosing Icaritin Ph Ib clinical trial results”. Icaritin is a first-in-class natural product developed by Shenogen. It is derived from a traditional Chinese medicine (TCM) and currently in Ph II clinical trial. The first indication is hepatocellular carcinoma (HCC).
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.